亚急性肺部疾病中的肺表面活性物质
Lung surfactant in subacute pulmonary disease.
作者信息
Devendra Gehan, Spragg Roger G
机构信息
University of California, San Diego, California, USA.
出版信息
Respir Res. 2002;3(1):19. doi: 10.1186/rr168. Epub 2002 Apr 4.
Abstract
Pulmonary surfactant is a surface active material composed of both lipids and proteins that is produced by alveolar type II pneumocytes. Abnormalities of surfactant in the immature lung or in the acutely inflamed mature lung are well described. However, in a variety of subacute diseases of the mature lung, abnormalities of lung surfactant may also be of importance. These diseases include chronic obstructive pulmonary disease, asthma, cystic fibrosis, interstitial lung disease, pneumonia, and alveolar proteinosis. Understanding of the mechanisms that disturb the lung surfactant system may lead to novel rational therapies for these diseases.
摘要
肺表面活性物质是一种由脂质和蛋白质组成的表面活性物质，由II型肺泡上皮细胞产生。未成熟肺或急性炎症成熟肺中表面活性物质的异常已有充分描述。然而，在成熟肺的各种亚急性疾病中，肺表面活性物质异常也可能很重要。这些疾病包括慢性阻塞性肺疾病、哮喘、囊性纤维化、间质性肺疾病、肺炎和肺泡蛋白沉积症。了解干扰肺表面活性物质系统的机制可能会为这些疾病带来新的合理治疗方法。
相似文献
1
Lung surfactant in subacute pulmonary disease.亚急性肺部疾病中的肺表面活性物质
Respir Res. 2002;3(1):19. doi: 10.1186/rr168. Epub 2002 Apr 4.
2
Pulmonary surfactant in health and human lung diseases: state of the art.健康与人类肺部疾病中的肺表面活性物质：最新进展
Eur Respir J. 1999 Jun;13(6):1455-76. doi: 10.1183/09031936.99.13614779.
3
[Pulmonary surfactant homeostasis associated genetic abnormalities and lung diseases].[肺表面活性物质稳态相关基因异常与肺部疾病]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2016 Aug;33(4):564-8. doi: 10.3760/cma.j.issn.1003-9406.2016.04.031.
4
Genetic mechanisms of surfactant deficiency.表面活性剂缺乏的遗传机制。
Biol Neonate. 2004;85(4):314-8. doi: 10.1159/000078171. Epub 2004 Jun 8.
5
Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.用于治疗新生儿呼吸窘迫综合征和小儿肺部疾病的肺表面活性剂的演变
Acta Paediatr. 2006 Sep;95(9):1036-48. doi: 10.1080/08035250600615168.
6
Diseases of pulmonary surfactant homeostasis.肺表面活性物质稳态相关疾病。
Annu Rev Pathol. 2015;10:371-93. doi: 10.1146/annurev-pathol-012513-104644.
7
The role of surfactant in asthma.表面活性剂在哮喘中的作用。
Respir Res. 2002;3(1):4. doi: 10.1186/rr176. Epub 2001 Oct 15.
8
The molecular era of surfactant biology.表面活性剂生物学的分子时代。
Neonatology. 2014;105(4):337-43. doi: 10.1159/000360649. Epub 2014 May 30.
9
Surfactant apoprotein in nonmalignant pulmonary disorders.非恶性肺部疾病中的表面活性物质载脂蛋白
Am J Pathol. 1980 Oct;101(1):51-61.
10
The surfactant system protects both fetus and newborn.表面活性剂系统可保护胎儿和新生儿。
Neonatology. 2013;103(4):320-6. doi: 10.1159/000349994. Epub 2013 May 31.
引用本文的文献
1
Exploring the metabolomics and metagenomics of chronic obstructive pulmonary disease (COPD) and lung cancer: unraveling the complex interplay.探索慢性阻塞性肺疾病（COPD）和肺癌的代谢组学与宏基因组学：揭示复杂的相互作用。
J Thorac Dis. 2025 Jul 31;17(7):5268-5281. doi: 10.21037/jtd-2025-278. Epub 2025 Jul 29.
2
Comprehensive characterization of human alveolar epithelial cells cultured for 28 days at the air-liquid interface.对在气液界面培养28天的人肺泡上皮细胞进行全面表征。
Sci Rep. 2025 Jul 2;15(1):22995. doi: 10.1038/s41598-025-07219-8.
3
The Application of Fluorescence Anisotropy for Viscosity Measurements of Small Volume Biological Analytes.荧光各向异性在小体积生物分析物粘度测量中的应用。
J Exp Theor Anal. 2023 Dec;1(2):86-96. doi: 10.3390/jeta1020007. Epub 2023 Dec 1.
4
Exploring the Role of Biomarkers Associated with Alveolar Damage and Dysfunction in Idiopathic Pulmonary Fibrosis-A Systematic Review.探索与特发性肺纤维化中肺泡损伤和功能障碍相关的生物标志物的作用——一项系统综述
J Pers Med. 2023 Nov 14;13(11):1607. doi: 10.3390/jpm13111607.
5
A Potent Histone Deacetylase Inhibitor MPT0E028 Mitigates Emphysema Severity via Components of the Hippo Signaling Pathway in an Emphysematous Mouse Model.一种强效组蛋白去乙酰化酶抑制剂MPT0E028通过肺气肿小鼠模型中 Hippo 信号通路的组分减轻肺气肿严重程度。
Front Med (Lausanne). 2022 May 18;9:794025. doi: 10.3389/fmed.2022.794025. eCollection 2022.
6
Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity.肺表面活性剂中减少的 DMPC 和 PMPC 促进肥胖中的 SARS-CoV-2 感染。
Metabolism. 2022 Jun;131:155181. doi: 10.1016/j.metabol.2022.155181. Epub 2022 Mar 18.
7
Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids.阴离子肺表面活性剂磷脂的抗炎和抗病毒作用。
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jun;1867(6):159139. doi: 10.1016/j.bbalip.2022.159139. Epub 2022 Feb 28.
8
Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse.黏多糖贮积症 IIIA 型小鼠肺泡肝素硫酸含量增加和肺表面活性物质含量及功能降低。
Cells. 2021 Apr 8;10(4):849. doi: 10.3390/cells10040849.
9
Scavenger Receptor Class B type 1 (SR-B1) and the modifiable risk factors of stroke.B1型清道夫受体（SR-B1）与中风的可改变风险因素
Chin Neurosurg J. 2019 Dec 17;5:30. doi: 10.1186/s41016-019-0178-3. eCollection 2019.
10
Alveolar lipids in pulmonary disease. A review.肺部疾病中的肺泡脂质。综述。
Lipids Health Dis. 2020 Jun 3;19(1):122. doi: 10.1186/s12944-020-01278-8.
本文引用的文献
1
Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis.表面活性蛋白A和其他支气管肺泡灌洗液蛋白在囊性纤维化中会发生改变。
Eur Respir J. 2001 Apr;17(4):716-22. doi: 10.1183/09031936.01.17407160.
2
Compositional and functional changes of pulmonary surfactant in a guinea-pig model of chronic asthma.慢性哮喘豚鼠模型中肺表面活性物质的组成和功能变化
Respir Med. 2001 Mar;95(3):180-6. doi: 10.1053/rmed.2000.1012.
3
Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia.急性呼吸窘迫综合征和重症肺炎中不同肺表面活性物质磷脂脂肪酸谱的改变
Am J Respir Crit Care Med. 2001 Jan;163(1):95-100. doi: 10.1164/ajrccm.163.1.9903029.
4
A mutation in the surfactant protein C gene associated with familial interstitial lung disease.与家族性间质性肺病相关的表面活性蛋白C基因突变。
N Engl J Med. 2001 Feb 22;344(8):573-9. doi: 10.1056/NEJM200102223440805.
5
Surfactant proteins a and d and pulmonary host defense.表面活性蛋白A和D与肺部宿主防御
Annu Rev Physiol. 2001;63:521-54. doi: 10.1146/annurev.physiol.63.1.521.
6
Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis.对于进行性系统性硬化症患者，血清表面活性蛋白A和D水平是间质性肺病的有用生物标志物。
Am J Respir Crit Care Med. 2000 Jul;162(1):258-63. doi: 10.1164/ajrccm.162.1.9903014.
7
Carbon dioxide enhances nitration of surfactant protein A by activated alveolar macrophages.二氧化碳可增强活化肺泡巨噬细胞对表面活性蛋白A的硝化作用。
Am J Physiol Lung Cell Mol Physiol. 2000 May;278(5):L1025-31. doi: 10.1152/ajplung.2000.278.5.L1025.
8
Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis.外源性粒细胞巨噬细胞集落刺激因子治疗肺泡蛋白沉积症。
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1143-8. doi: 10.1164/ajrccm.161.4.9906044.
9
Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis.特发性肺纤维化、过敏性肺炎和结节病中的表面活性剂异常。
Eur Respir J. 1999 Sep;14(3):565-73. doi: 10.1034/j.1399-3003.1999.14c14.x.
10
Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.特发性肺泡蛋白沉积症是一种针对粒细胞/巨噬细胞集落刺激因子具有中和抗体的自身免疫性疾病。
J Exp Med. 1999 Sep 20;190(6):875-80. doi: 10.1084/jem.190.6.875.
Zotero 插件